The recall represents around 2.5% of doses sold in the United States in 2025.

Boehringer Ingelheim, a global leader in animal health, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorizations (EUA) for the use of NexGard (R) ...

FDA grants first Emergency Use Authorization for an over-the-counter product for the prevention of New World screwworm infestations in cattle -- Ongoing detections in Mexico heighten the importance of ...

Boehringer Ingelheim will provide NIPER Raebareli access to the opnMe portal, facilitating scientific advancement in ...

Boehringer Ingelheim is discarding an inhaled gene therapy designed to treat cystic fibrosis (CF) after terminating a phase 1/2 trial. | Boehringer Ingelheim is discarding an inhaled gene therapy ...

Please provide your email address to receive an email when new articles are posted on . Quallent will offer both low- and high-concentration citrate-free adalimumab-adbm. The existing biosimilar ...

Boehringer Ingelheim unveiled its evolved company brand this week, featuring the corporate claim: “Life forward.” The German pharma giant said the claim builds upon the company’s purpose of ...

Please provide your email address to receive an email when new articles are posted on . The companies will work together to develop sustained-release ophthalmic therapies. The deal has a potential ...

A Boehringer Ingelheim drug in development for weight loss now has data from a separate mid-stage clinical trial showing dramatic reductions across several measures of a fatty liver disease whose ...

Boehringer Ingelheim announced it will buy Nerio Therapeutics for $1.3 billion Monday morning. The German drugmaker is bolstering its immuno-oncology pipeline by adding the San Diego-based drug ...

INGELHEIM, Germany & BASEL, Switzerland--(BUSINESS WIRE)--Boehringer Ingelheim today announced the acquisition of privately-held T3 Pharmaceuticals AG (“T3 Pharma”), a clinical stage Swiss biotech ...